#nct_id	eligibility_type	criterion	label	term	ner_score	concepts	tree_numbers	nel_score
NCT04346355	inclusion	Real time polymerase chain reaction (PCR) diagnosis of Sars-CoV2 infection	word_scores:chronic_disease	sars-cov2 infection	0.925	COVID-19	C01.925	1.000
NCT04346355	inclusion	Hospitalization due to clinical / instrumental diagnosis (high resolution chest CT scan or chest x-ray or pulmonary ultrasound)	word_scores:treatment	chest ct scan chest x-ray pulmonary ultrasound	0.899
NCT04346355	inclusion	Presence of acute respiratory distress syndrome with arterial partial pressure of oxygen / fraction of inspired oxygen (PaO2 / FiO2) between 200 and 300 mm/Hg	word_scores:chronic_disease	acute respiratory distress syndrome	0.964	Respiratory Distress Syndrome, Adult	C08.381.840|C08.618.840	1.000
NCT04346355	inclusion	Presence of exaggerated inflammatory response defined by the presence of at least 1 of the following criteria: Serum CRP greater than or equal to 10 mg/dl	word_scores:clinical_variable	serum crp	0.946
NCT04346355	exclusion	Patients with respiratory distress syndrome with arterial partial pressure of oxygen / fraction of inspired oxygen (PaO2 / FiO2) <200 mm/Hg or	word_scores:chronic_disease	respiratory distress syndrome	0.982	Respiratory Distress Syndrome, Adult	C08.381.840|C08.618.840	1.000
NCT04346355	exclusion	Patients with respiratory distress syndrome with arterial partial pressure of oxygen / fraction of inspired oxygen (PaO2 / FiO2) <200 mm/Hg or	word_scores:clinical_variable	oxygen / fraction inspired oxygen	0.777
NCT04346355	exclusion	Patients in non-invasive ventilation or	word_scores:treatment	non-invasive ventilation	0.947	Noninvasive Ventilation	E02.041.625.591|E02.880.820.657	1.000
NCT04346355	exclusion	Severe heart and kidney failure	word_scores:chronic_disease	severe heart kidney failure	0.924	Heart	A07.541	1.000
NCT04346355	exclusion	Severe heart and kidney failure	word_scores:chronic_disease	severe heart kidney failure	0.924	Kidney Failure	C12.777.419.780|C13.351.968.419.780	1.000
NCT04346355	exclusion	Pregnant or breastfeeding patient	word_scores:pregnancy	pregnant	1.000	Pregnancy	G08.686.784.769	1.000
NCT04346355	exclusion	Known hypersensitivity to TCZ or its excipients	word_scores:allergy_name	tcz	0.991
NCT04346355	exclusion	Patient being treated with immuno-depressors or anti-rejection drugs	word_scores:treatment	immuno-depressors anti-rejection drugs	0.994
NCT04346355	exclusion	Known active infections or other clinical conditions that contraindicate TCZ and cannot be treated or resolved according to the physician's judgment	word_scores:chronic_disease	active infections	0.774
NCT04346355	exclusion	glutamate-pyruvate transaminase (GPT) or glutamine oxaloacetic transaminase (GOT) > 5 times the upper limit of the norm	word_scores:clinical_variable	glutamate-pyruvate transaminase glutamine oxaloacetic transaminase	0.978	Aspartate Aminotransferases	D08.811.913.477.700.225	0.765
NCT04346355	exclusion	Neutrophils <500 /mmc	word_scores:clinical_variable	neutrophils	0.996	Neutrophils	A11.118.637.415.583|A11.627.340.583|A11.733.689|A15.145.229.637.415.583|A15.382.490.315.583|A15.382.680.689	1.000
NCT04346355	exclusion	Platelets <50.000 /mmc	word_scores:clinical_variable	platelets	0.999	Blood Platelets	A11.118.188|A15.145.229.188	1.000
NCT04346355	exclusion	Diverticulitis or intestinal perforation	word_scores:chronic_disease	diverticulitis intestinal perforation	0.996	Diverticulitis	C06.405.205.282.500	1.000
NCT04346355	exclusion	Diverticulitis or intestinal perforation	word_scores:chronic_disease	diverticulitis intestinal perforation	0.996	Intestinal Perforation	C06.405.469.557	1.000
NCT04346355	exclusion	Suspicion of latent tuberculosis	word_scores:chronic_disease	latent tuberculosis	0.997	Latent Tuberculosis	C01.150.252.410.040.552.846.122	1.000
NCT04344951	inclusion	For women of childbearing age, they should use or be willing to use a double contraceptive method during the study. A urine pregnancy test to exclude pregnancy will be performed prior to study initiation	word_scores:gender	women	0.999	Women	M01.975	1.000
NCT04344951	inclusion	For women of childbearing age, they should use or be willing to use a double contraceptive method during the study. A urine pregnancy test to exclude pregnancy will be performed prior to study initiation	word_scores:contraception_consent	use be willing to use a double contraceptive method	0.957
NCT04344951	inclusion	For women of childbearing age, they should use or be willing to use a double contraceptive method during the study. A urine pregnancy test to exclude pregnancy will be performed prior to study initiation	word_scores:pregnancy	urine pregnancy test	0.854
NCT04344951	inclusion	For women of childbearing age, they should use or be willing to use a double contraceptive method during the study. A urine pregnancy test to exclude pregnancy will be performed prior to study initiation	word_scores:pregnancy	pregnancy will	0.886
NCT04344951	inclusion	Upper respiratory or lower respiratory tract infection, as in Annexes II and III respectively	word_scores:chronic_disease	upper respiratory lower respiratory tract infection	0.928	Upper Respiratory Tract Infections	C01.748|C08.730	1.000
NCT04344951	inclusion	Positive respiratory secretion test for SARS-CoV-2 virus by molecular techniques or positive blood IgM titers	word_scores:chronic_disease	respiratory secretion	0.714
NCT04344951	exclusion	Serum AST values greater than 5 times the upper normal range	word_scores:clinical_variable	serum ast values	0.969
NCT04344951	exclusion	Pregnancy or lactation. Urgent pregnancy test to exclude pregnancy before inclusion in the study	word_scores:pregnancy	pregnancy	0.998	Pregnancy	G08.686.784.769	1.000
NCT04344951	exclusion	Pregnancy or lactation. Urgent pregnancy test to exclude pregnancy before inclusion in the study	word_scores:pregnancy	pregnancy test	0.889	Pregnancy Tests	E01.370.225.970|E01.370.378.620|E05.200.970	1.000
NCT04344951	exclusion	Pregnancy or lactation. Urgent pregnancy test to exclude pregnancy before inclusion in the study	word_scores:pregnancy	pregnancy	0.883	Pregnancy	G08.686.784.769	1.000
NCT04344444	inclusion	Oxygen saturation of >94% on room air with defined risk factors (Table 1) consistent with moderate disease OR oxygen saturation of < 94% on room air consistent with severe disease	word_scores:clinical_variable	oxygen saturation	0.925
NCT04344444	inclusion	Oxygen saturation of >94% on room air with defined risk factors (Table 1) consistent with moderate disease OR oxygen saturation of < 94% on room air consistent with severe disease	word_scores:clinical_variable	oxygen saturation	0.799
NCT04344444	exclusion	QTc greater than 450 milliseconds on screening EKG	word_scores:clinical_variable	qtc	0.981
NCT04344444	exclusion	Pregnant or lactating women	word_scores:pregnancy	pregnant	0.999	Pregnancy	G08.686.784.769	1.000
NCT04344444	exclusion	Pregnant or lactating women	word_scores:gender	women	0.997	Women	M01.975	1.000
NCT04344444	exclusion	Inability to take oral pills or inability to use a feeding tube	word_scores:treatment	oral pills	0.899
NCT04344444	exclusion	use of azithromycin or hydroxychloroquine within 30 days prior to admission	word_scores:treatment	azithromycin hydroxychloroquine	0.919	Azithromycin	D02.540.576.500.992.050	1.000
NCT04344444	exclusion	use of azithromycin or hydroxychloroquine within 30 days prior to admission	word_scores:treatment	azithromycin hydroxychloroquine	0.919	Hydroxychloroquine	D03.633.100.810.050.180.350	1.000
NCT04344080	inclusion	confirmed COVID-19 disease	word_scores:chronic_disease	covid-19 disease	0.972	COVID-19	C01.925	1.000
NCT04344080	inclusion	refractory shock with need for norepinephrine ≥ 0.2 μg/kg/min for MAP ≥ 65 mmHg	word_scores:clinical_variable	norepinephrine	0.837	Norepinephrine	D02.033.100.291.502|D02.092.063.480|D02.092.211.215.746|D02.092.311.830|D02.455.426.559.389.657.166.175.830	1.000
NCT04344080	inclusion	IL6 ≥ 500 ng/l	word_scores:clinical_variable	il6	0.981	Interleukin-6	D12.644.276.374.465.224|D12.776.467.374.465.202|D23.529.374.465.224	1.000
NCT04344080	inclusion	Indication for CRRT or ECMO	word_scores:treatment	crrt ecmo	0.985	Extracorporeal Membrane Oxygenation	E02.880.301|E04.292.451	1.000
NCT04344080	exclusion	Liver cirrhosis Child Pugh C	word_scores:chronic_disease	liver cirrhosis child pugh c	0.725
NCT04344080	exclusion	pregnancy or breastfeeding	word_scores:pregnancy	pregnancy	0.999	Pregnancy	G08.686.784.769	1.000
NCT04344080	exclusion	participation in another interventional trial	word_scores:treatment	interventional trial	0.987
NCT04344015	inclusion	Prior diagnosis of COVID-19 documented by a laboratory test approved by the FDA	word_scores:chronic_disease	covid-19 documented	0.951	COVID-19	C01.925	1.000
NCT04344015	inclusion	Male donors, never-pregnant female donors, or previously pregnant female donors negative for HLA antibodies	word_scores:pregnancy	previously pregnant female	0.923
NCT04344015	inclusion	Male donors, never-pregnant female donors, or previously pregnant female donors negative for HLA antibodies	word_scores:gender	male donors	0.996
NCT04344015	inclusion	Male donors, never-pregnant female donors, or previously pregnant female donors negative for HLA antibodies	word_scores:gender	female donors	0.874
NCT04344015	inclusion	Male donors, never-pregnant female donors, or previously pregnant female donors negative for HLA antibodies	word_scores:gender	donors	0.855	Donors	M01.898	1.000
NCT04344015	exclusion	Female donors with HLA antibodies (per FDA requirements for convalescent plasma donors)	word_scores:gender	female donors	0.893
NCT04344015	exclusion	Currently pregnant	word_scores:pregnancy	pregnant	0.949	Pregnancy	G08.686.784.769	1.000
NCT04343989	inclusion	Confirmed COVID-19 disease (by Cobas SARS-CoV-2 real time RT-PCR using nasopharyngeal swab sample, or equivalent test available to be performed by the NYU Langone clinical laboratory). Effort will be made to have the confirmatory test result <72 hours prior to enrollment however given overall clinical demand this may not be feasible in all cases	word_scores:chronic_disease	covid-19 disease	0.773	COVID-19	C01.925	1.000
NCT04343989	inclusion	Respiratory failure manifesting as: Acute Respiratory Distress Syndrome (defined by a P/F ratio of <200), OR SpO2 < 90% on 4L (actual or expected given higher O2 requirement) OR increasing O2 requirements over 24 hours, PLUS 2 or more of the following predictors for severe disease	word_scores:chronic_disease	respiratory failure manifesting	0.924
NCT04343989	inclusion	Respiratory failure manifesting as: Acute Respiratory Distress Syndrome (defined by a P/F ratio of <200), OR SpO2 < 90% on 4L (actual or expected given higher O2 requirement) OR increasing O2 requirements over 24 hours, PLUS 2 or more of the following predictors for severe disease	word_scores:chronic_disease	acute respiratory distress syndrome	0.900	Respiratory Distress Syndrome, Adult	C08.381.840|C08.618.840	1.000
NCT04343989	inclusion	Respiratory failure manifesting as: Acute Respiratory Distress Syndrome (defined by a P/F ratio of <200), OR SpO2 < 90% on 4L (actual or expected given higher O2 requirement) OR increasing O2 requirements over 24 hours, PLUS 2 or more of the following predictors for severe disease	word_scores:clinical_variable	spo2	0.783
NCT04343989	inclusion	CRP > 35 mg/L Ferritin > 500 ng/mL D-dimer > 1 mcg/L Neutrophil-Lymphocyte Ratio > 4 LDH > 200 U/L Increase in troponin in patient w/out known cardiac disease	word_scores:clinical_variable	crp	0.941
NCT04343989	inclusion	CRP > 35 mg/L Ferritin > 500 ng/mL D-dimer > 1 mcg/L Neutrophil-Lymphocyte Ratio > 4 LDH > 200 U/L Increase in troponin in patient w/out known cardiac disease	word_scores:clinical_variable	ratio	0.771
NCT04343989	inclusion	CRP > 35 mg/L Ferritin > 500 ng/mL D-dimer > 1 mcg/L Neutrophil-Lymphocyte Ratio > 4 LDH > 200 U/L Increase in troponin in patient w/out known cardiac disease	word_scores:chronic_disease	cardiac disease	0.837	Heart Diseases	C14.280	1.000
NCT04343989	inclusion	Women of childbearing potential must be willing and able to use at least one highly effective contraceptive method for a period of 5 months following the study drug administration. In the context of this study, an effective method is defined as those which result in low failure rate (i.e. less than 1% per year) when used consistently and correctly such as	word_scores:gender	women	1.000	Women	M01.975	1.000
NCT04343989	inclusion	Women of childbearing potential must be willing and able to use at least one highly effective contraceptive method for a period of 5 months following the study drug administration. In the context of this study, an effective method is defined as those which result in low failure rate (i.e. less than 1% per year) when used consistently and correctly such as	word_scores:contraception_consent	able to use one highly effective contraceptive method	0.865
NCT04343989	inclusion	combined (estrogen and progestogen containing) hormonal contraception combined (estrogen and progestogen containing) hormonal contraception (oral, intravaginal, or transdermal)	word_scores:contraception_consent	progestogen containing hormonal contraception combined	0.840
NCT04343989	inclusion	combined (estrogen and progestogen containing) hormonal contraception combined (estrogen and progestogen containing) hormonal contraception (oral, intravaginal, or transdermal)	word_scores:contraception_consent	estrogen progestogen containing hormonal contraception	0.855	Estrogens	D27.505.696.399.472.277	1.000
NCT04343989	inclusion	combined (estrogen and progestogen containing) hormonal contraception combined (estrogen and progestogen containing) hormonal contraception (oral, intravaginal, or transdermal)	word_scores:contraception_consent	transdermal	0.875
NCT04343989	inclusion	progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable)	word_scores:contraception_consent	progestogen-only hormonal contraception associated	0.743
NCT04343989	inclusion	progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable)	word_scores:treatment	oral	0.774	Oral Stage	F01.752.747.722.626|F02.739.794.793.626	1.000
NCT04343989	inclusion	progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable)	word_scores:treatment	injectable implantable	0.744	Contraceptives, Injections, Consent	CC01.01.01.04	0.875
NCT04343989	inclusion	progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable)	word_scores:treatment	injectable implantable	0.744	Contraceptives, Implant, Consent	CC01.03.02	1.000
NCT04343989	inclusion	intrauterine device (IUD)	word_scores:contraception_consent	intrauterine device	0.969	Intrauterine Devices, Consent	CC01.03.01	1.000
NCT04343989	inclusion	intrauterine hormone-releasing system (IUS)	word_scores:treatment	intrauterine hormone-releasing system	0.815
NCT04343989	inclusion	true abstinence. when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence, such as calendar, ovulation, symptothermal, postovulation methods, and withdrawal are not acceptable methods of contraception	word_scores:contraception_consent	methods contraception	0.833
NCT04343989	inclusion	Men must be willing to use a double-barrier contraception from enrollment until at 5 months after the last dose of study drug, if not abstinent	word_scores:gender	men must	0.999
NCT04343989	inclusion	Men must be willing to use a double-barrier contraception from enrollment until at 5 months after the last dose of study drug, if not abstinent	word_scores:contraception_consent	willing to use a double-barrier contraception from	0.971
NCT04343989	exclusion	Known active inflammatory bowel disease	word_scores:chronic_disease	inflammatory bowel disease	0.995	Inflammatory Bowel Diseases	C06.405.205.731|C06.405.469.432	1.000
NCT04343989	exclusion	Known active, untreated diverticulitis	word_scores:chronic_disease	diverticulitis	0.999	Diverticulitis	C06.405.205.282.500	1.000
NCT04343989	exclusion	Known untreated bacteremia	word_scores:chronic_disease	bacteremia	0.998	Bacteremia	C01.150.252.100|C01.757.100|C23.550.470.790.500.100	1.000
NCT04343989	exclusion	Pregnancy. (The protocol will exclude pregnant subjects given the lack of overall data on use of clazakizumab in pregnancy however the study team would consider a protocol revision should more than 3 potential pregnant study subjects be excluded on this basis)	word_scores:pregnancy	pregnancy	0.996	Pregnancy	G08.686.784.769	1.000
NCT04343989	exclusion	Pregnancy. (The protocol will exclude pregnant subjects given the lack of overall data on use of clazakizumab in pregnancy however the study team would consider a protocol revision should more than 3 potential pregnant study subjects be excluded on this basis)	word_scores:pregnancy	pregnant	0.949	Pregnancy	G08.686.784.769	1.000
NCT04343989	exclusion	Pregnancy. (The protocol will exclude pregnant subjects given the lack of overall data on use of clazakizumab in pregnancy however the study team would consider a protocol revision should more than 3 potential pregnant study subjects be excluded on this basis)	word_scores:pregnancy	pregnancy however	0.863
NCT04343989	exclusion	Pregnancy. (The protocol will exclude pregnant subjects given the lack of overall data on use of clazakizumab in pregnancy however the study team would consider a protocol revision should more than 3 potential pregnant study subjects be excluded on this basis)	word_scores:pregnancy	pregnant study	0.782
NCT04343989	exclusion	Known hypersensitivity to the clazakizumab	word_scores:allergy_name	clazakizumab	0.990
NCT04342182	inclusion	Patients with PCR confirmed COVID disease	word_scores:chronic_disease	covid disease	0.909	COVID-19	C01.925	1.000
NCT04342182	inclusion	A history of COVID infection that was documented by PCR	word_scores:chronic_disease	covid infection	0.967	COVID-19	C01.925	1.000
NCT04342182	inclusion	Known ABO-Resus(D) blood group	word_scores:chronic_disease	abo-resus	0.846
NCT04342182	inclusion	A negative screening for irregular antibodies	word_scores:treatment	irregular antibodies	0.841
NCT04342182	inclusion	Donors will be restricted to those who had a symptomatic COVID infection defined as documented fever 38.0 or higher C for at least 48 hours	word_scores:chronic_disease	covid infection	0.863	COVID-19	C01.925	1.000
NCT04342182	inclusion	Written informed consent regarding the plasmapheresis procedure	word_scores:treatment	plasmapheresis procedure	0.869
NCT04342182	exclusion	Weight <45kg	word_scores:clinical_variable	weight	0.997	Weights	E05.978	0.750
NCT04342182	exclusion	Medical history of heart failure	word_scores:chronic_disease	heart failure	0.999	Heart Failure	C14.280.434	1.000
NCT04342182	exclusion	History of transfusion with red blood cells, platelets or plasma	word_scores:treatment	transfusion	0.796
NCT04342182	exclusion	Born as a female person. The reason for this is a higher incidence of transfusion related acute lung injury (TRALI) after plasma transfusion from a female donor	word_scores:gender	female person	0.999
NCT04342182	exclusion	Born as a female person. The reason for this is a higher incidence of transfusion related acute lung injury (TRALI) after plasma transfusion from a female donor	word_scores:gender	female donor	0.980
NCT04341389	inclusion	Negative in HIV diagnostic test	word_scores:chronic_disease	hiv diagnostic	0.954	HIV	B04.820.650.589.650.350	1.000
NCT04341389	inclusion	Axillary temperature ≤37.0°C	word_scores:clinical_variable	axillary temperature	0.990
NCT04341389	exclusion	Family history of seizure, epilepsy, brain or mental disease	word_scores:chronic_disease	seizure epilepsy brain mental disease	0.996	Seizures	C10.597.742|C23.888.592.742	1.000
NCT04341389	exclusion	Family history of seizure, epilepsy, brain or mental disease	word_scores:chronic_disease	seizure epilepsy brain mental disease	0.996	Epilepsy	C10.228.140.490	1.000
NCT04341389	exclusion	Family history of seizure, epilepsy, brain or mental disease	word_scores:chronic_disease	seizure epilepsy brain mental disease	0.996	Brain	A08.186.211	1.000
NCT04341389	exclusion	Subject allergic to any component of the investigational vaccine, or a more severe allergic reaction and history of allergies in the past	word_scores:allergy_name	investigational vaccine	0.846
NCT04341389	exclusion	Woman who is pregnant, breast-feeding or positive in β-HCG (human chorionic gonadotropin) pregnancy test (urine) on day of enrollment, or become pregnant during the next 6 months	word_scores:gender	woman	0.999	Women	M01.975	1.000
NCT04341389	exclusion	Woman who is pregnant, breast-feeding or positive in β-HCG (human chorionic gonadotropin) pregnancy test (urine) on day of enrollment, or become pregnant during the next 6 months	word_scores:pregnancy	pregnant	0.982	Pregnancy	G08.686.784.769	1.000
NCT04341389	exclusion	Woman who is pregnant, breast-feeding or positive in β-HCG (human chorionic gonadotropin) pregnancy test (urine) on day of enrollment, or become pregnant during the next 6 months	word_scores:pregnancy	gonadotropin pregnancy test	0.732
NCT04341389	exclusion	Woman who is pregnant, breast-feeding or positive in β-HCG (human chorionic gonadotropin) pregnancy test (urine) on day of enrollment, or become pregnant during the next 6 months	word_scores:pregnancy	become pregnant	0.928	Pregnancy	G08.686.784.769	1.000
NCT04341389	exclusion	Any acute fever disease or infections	word_scores:chronic_disease	acute fever disease infections	0.882	Infections	C01	1.000
NCT04341389	exclusion	History of SARS	word_scores:chronic_disease	sars	0.952	Severe Acute Respiratory Syndrome	C01.748.730|C01.925.782.600.550.200.750|C08.730.730	1.000
NCT04341389	exclusion	Major congenital defects or not well-controlled chronic illness, such as asthma, diabetes, or thyroid disease	word_scores:chronic_disease	chronic illness	0.759	Chronic Disease	C23.550.291.500	1.000
NCT04341389	exclusion	Major congenital defects or not well-controlled chronic illness, such as asthma, diabetes, or thyroid disease	word_scores:chronic_disease	asthma diabetes	0.995	Asthma	C08.127.108|C08.381.495.108|C08.674.095|C20.543.480.680.095	1.000
NCT04341389	exclusion	Major congenital defects or not well-controlled chronic illness, such as asthma, diabetes, or thyroid disease	word_scores:chronic_disease	asthma diabetes	0.995	Diabetes Mellitus	C18.452.394.750|C19.246	1.000
NCT04341389	exclusion	Major congenital defects or not well-controlled chronic illness, such as asthma, diabetes, or thyroid disease	word_scores:chronic_disease	thyroid disease	0.998	Thyroid Diseases	C19.874	1.000
NCT04341389	exclusion	Serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, severe hypertension without controllable drugs, etc	word_scores:chronic_disease	cardiovascular diseases	0.976	Cardiovascular Diseases	C14	1.000
NCT04341389	exclusion	Serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, severe hypertension without controllable drugs, etc	word_scores:chronic_disease	arrhythmia conduction block myocardial infarction	0.968	Arrhythmias, Cardiac	C14.280.067|C23.550.073	1.000
NCT04341389	exclusion	Serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, severe hypertension without controllable drugs, etc	word_scores:chronic_disease	arrhythmia conduction block myocardial infarction	0.968	Myocardial Infarction	C14.280.647.500|C14.907.585.500|C23.550.513.355.750|C23.550.717.489.750	1.000
NCT04341389	exclusion	Serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, severe hypertension without controllable drugs, etc	word_scores:chronic_disease	hypertension	0.970	Hypertension	C14.907.489	1.000
NCT04341389	exclusion	Hereditary angioneurotic edema or acquired angioneurotic edema	word_scores:chronic_disease	hereditary angioneurotic edema	0.892	Angioedemas, Hereditary	C14.907.079.500|C16.320.798.500.500|C17.800.862.945.066.500|C20.543.480.904.066.500|C20.673.795.500.500	1.000
NCT04341389	exclusion	Hereditary angioneurotic edema or acquired angioneurotic edema	word_scores:chronic_disease	angioneurotic edema	0.929	Angioedema	C14.907.079|C17.800.862.945.066|C20.543.480.904.066	1.000
NCT04341389	exclusion	No spleen or functional spleen	word_scores:chronic_disease	functional spleen	0.838
NCT04341389	exclusion	Platelet disorder or other bleeding disorder may cause injection contraindication	word_scores:chronic_disease	platelet disorder	0.976	Blood Platelet Disorders	C15.378.140	1.000
NCT04341389	exclusion	Platelet disorder or other bleeding disorder may cause injection contraindication	word_scores:chronic_disease	bleeding disorder	0.919	Feeding Disorders	F03.400	0.800
NCT04341389	exclusion	Prior administration of immunodepressant or corticosteroids, antianaphylaxis treatment, cytotoxic treatment in last 6 months	word_scores:treatment	immunodepressant corticosteroids antianaphylaxis treatment cytotoxic treatment	0.969	Adrenal Cortex Hormones	D06.472.040	1.000
NCT04341389	exclusion	Prior administration of immunodepressant or corticosteroids, antianaphylaxis treatment, cytotoxic treatment in last 6 months	word_scores:treatment	immunodepressant corticosteroids antianaphylaxis treatment cytotoxic treatment	0.969	Antibiotics, Cytotoxic	D27.505.954.248.106	1.000
NCT04341389	exclusion	Prior administration of other research medicines in last 1 month	word_scores:treatment	medicines	0.790
NCT04341389	exclusion	Prior administration of attenuated vaccine in last 1 month	word_scores:treatment	attenuated vaccine	0.989	Vaccines, Attenuated	D20.215.894.811	0.938
NCT04341389	exclusion	Prior administration of inactivated vaccine in last 14 days	word_scores:treatment	inactivated vaccine	0.947	Vaccines, Inactivated	D20.215.894.830	0.941
NCT04341389	exclusion	Current anti-tuberculosis prophylaxis or therapy	word_scores:treatment	anti-tuberculosis prophylaxis therapy	0.986	Therapeutics	E02	1.000
NCT04341389	exclusion	According to the judgement of investigator,various medical, psychological, social or other conditions, those could affect the subjects to sign informed consent	word_scores:chronic_disease	psychological	0.765
NCT04340557	inclusion	Mild to moderate respiratory disease defined by oxygen requirement of at least 2 L/min to maintain oxygen saturation level ≥92%	word_scores:chronic_disease	respiratory disease	0.768
NCT04340557	inclusion	Mild to moderate respiratory disease defined by oxygen requirement of at least 2 L/min to maintain oxygen saturation level ≥92%	word_scores:clinical_variable	oxygen saturation level	0.781
NCT04340557	inclusion	Systolic blood pressure ≥ 110 mmHg	word_scores:clinical_variable	systolic blood pressure	0.998
NCT04340557	inclusion	Access to an electronic device that is able to access DocuSign® online and email for consenting	word_scores:technology_access	access to an electronic device able to access docusign®	0.884
NCT04340557	inclusion	Able to read/write/speak English or Spanish fluently	word_scores:language_fluency	able to read / write / speak english spanish fluently	0.986
NCT04340557	inclusion	Negative pregnancy test for women of childbearing potential	word_scores:pregnancy	negative pregnancy test	0.979	Pregnancy Tests	E01.370.225.970|E01.370.378.620|E05.200.970	1.000
NCT04340557	inclusion	Negative pregnancy test for women of childbearing potential	word_scores:gender	women	0.998	Women	M01.975	1.000
NCT04340557	exclusion	Severe allergy to any ARB or ACE-inhibitor, including angioedema	word_scores:allergy_name	arb ace-inhibitor	0.986
NCT04340557	exclusion	Severe allergy to any ARB or ACE-inhibitor, including angioedema	word_scores:allergy_name	angioedema	0.979	Angioedema	C14.907.079|C17.800.862.945.066|C20.543.480.904.066	1.000
NCT04340557	exclusion	Home meds include any kind of ACE inhibitor or ARB	word_scores:treatment	ace inhibitor arb	0.987	Angiotensin-Converting Enzyme Inhibitors	D27.505.519.389.745.085	0.909
NCT04340557	exclusion	SBP <110 mmHg	word_scores:clinical_variable	sbp	0.947
NCT04340557	exclusion	Acute Kidney Injury (50% reduction in GFR from baseline at admission to any time during treatment in the study treatment arm)	word_scores:chronic_disease	acute kidney injury	0.874	Acute Kidney Injury	C12.777.419.780.050|C13.351.968.419.780.050	1.000
NCT04340557	exclusion	Acute Kidney Injury (50% reduction in GFR from baseline at admission to any time during treatment in the study treatment arm)	word_scores:treatment	treatment	0.705	Therapeutics	E02	1.000
NCT04340557	exclusion	Hyperkalemia >5.0 mmol/L at baseline or any time during treatment in the study treatment arm	word_scores:clinical_variable	hyperkalemia	0.914	Hyperkalemia	C18.452.950.396	1.000
NCT04340557	exclusion	Hyperkalemia >5.0 mmol/L at baseline or any time during treatment in the study treatment arm	word_scores:treatment	treatment	0.701	Therapeutics	E02	1.000
NCT04340557	exclusion	Creatinine Clearance < 30 ml/min at baseline or any time during treatment in the study treatment arm	word_scores:clinical_variable	creatinine clearance	0.996
NCT04340050	inclusion	Prior diagnosis of COVID-19 documented by a laboratory test (confirmed)	word_scores:chronic_disease	covid-19 documented	0.849	COVID-19	C01.925	1.000
NCT04340050	inclusion	Female donors who have never been pregnant, previously pregnant female donors negative for HLA antibodies (HLA screening), or male donors	word_scores:gender	female donors	0.845
NCT04340050	inclusion	Female donors who have never been pregnant, previously pregnant female donors negative for HLA antibodies (HLA screening), or male donors	word_scores:gender	donors	0.893	Donors	M01.898	1.000
NCT04340050	inclusion	Female donors who have never been pregnant, previously pregnant female donors negative for HLA antibodies (HLA screening), or male donors	word_scores:pregnancy	been pregnant previously pregnant female	0.904
NCT04340050	inclusion	Must have severe or immediately life-threatening COVID-19	word_scores:chronic_disease	life-threatening covid-19	0.724
NCT04340050	inclusion	Severe defined as dyspnea, respiratory frequency ≥ 30/min, blood oxygen saturation ≤ 93%, partial pressure of arterial oxygen to fraction of inspired oxygen ratio < 300, and/or lung infiltrates > 50% within 24 to 48 hours	word_scores:chronic_disease	dyspnea	0.962	Dyspnea	C08.618.326|C23.888.852.371	1.000
NCT04340050	inclusion	Severe defined as dyspnea, respiratory frequency ≥ 30/min, blood oxygen saturation ≤ 93%, partial pressure of arterial oxygen to fraction of inspired oxygen ratio < 300, and/or lung infiltrates > 50% within 24 to 48 hours	word_scores:clinical_variable	blood oxygen saturation	0.838
NCT04340050	inclusion	Severe defined as dyspnea, respiratory frequency ≥ 30/min, blood oxygen saturation ≤ 93%, partial pressure of arterial oxygen to fraction of inspired oxygen ratio < 300, and/or lung infiltrates > 50% within 24 to 48 hours	word_scores:clinical_variable	inspired oxygen ratio	0.791
NCT04340050	inclusion	Severe defined as dyspnea, respiratory frequency ≥ 30/min, blood oxygen saturation ≤ 93%, partial pressure of arterial oxygen to fraction of inspired oxygen ratio < 300, and/or lung infiltrates > 50% within 24 to 48 hours	word_scores:clinical_variable	lung infiltrates	0.760
NCT04340050	inclusion	Life-threatening defined as respiratory failure, septic shock, and/or multiple organ dysfunction or failure. Lower priority should be given to patients with septic shock or multiple organ dysfunction or failure since their disease may have progressed to a point where they are not able to benefit from convalescent plasma therapy	word_scores:chronic_disease	respiratory failure septic shock	0.915	Respiratory Failure	C08.618.846	1.000
NCT04340050	inclusion	Life-threatening defined as respiratory failure, septic shock, and/or multiple organ dysfunction or failure. Lower priority should be given to patients with septic shock or multiple organ dysfunction or failure since their disease may have progressed to a point where they are not able to benefit from convalescent plasma therapy	word_scores:chronic_disease	respiratory failure septic shock	0.915	Shock, Septic	C01.757.800|C23.550.470.790.500.800|C23.550.835.900.712	1.000
NCT04340050	inclusion	Life-threatening defined as respiratory failure, septic shock, and/or multiple organ dysfunction or failure. Lower priority should be given to patients with septic shock or multiple organ dysfunction or failure since their disease may have progressed to a point where they are not able to benefit from convalescent plasma therapy	word_scores:chronic_disease	multiple organ dysfunction	0.906
NCT04340050	inclusion	Life-threatening defined as respiratory failure, septic shock, and/or multiple organ dysfunction or failure. Lower priority should be given to patients with septic shock or multiple organ dysfunction or failure since their disease may have progressed to a point where they are not able to benefit from convalescent plasma therapy	word_scores:chronic_disease	multiple organ dysfunction	0.726
NCT04340050	inclusion	Life-threatening defined as respiratory failure, septic shock, and/or multiple organ dysfunction or failure. Lower priority should be given to patients with septic shock or multiple organ dysfunction or failure since their disease may have progressed to a point where they are not able to benefit from convalescent plasma therapy	word_scores:treatment	convalescent plasma therapy	0.772
NCT04340050	exclusion	Female subjects with positive pregnancy test, breastfeeding, or planning to become pregnant/breastfeed during the study period	word_scores:gender	female	0.999	Women	M01.975	1.000
NCT04340050	exclusion	Female subjects with positive pregnancy test, breastfeeding, or planning to become pregnant/breastfeed during the study period	word_scores:pregnancy	positive pregnancy test	0.913	Pregnancy Tests	E01.370.225.970|E01.370.378.620|E05.200.970	1.000
NCT04340050	exclusion	Female subjects with positive pregnancy test, breastfeeding, or planning to become pregnant/breastfeed during the study period	word_scores:pregnancy	planning to become pregnant	0.937
NCT04340050	exclusion	Patients currently enrolled in other drug trials that preclude investigational treatment with anti-SARS-CoV-2 convalescent plasma	word_scores:treatment	investigational treatment anti-sars-cov-2 convalescent plasma	0.851
NCT04348032	inclusion	Patients were diagnosed with ovarian cancer, fallopian tube cancer or primary peritoneal cancer confirmed by previous pathology, and the pathological type was non-mucinous adenocarcinoma.There were previous surgical wax preservation	word_scores:cancer	ovarian cancer fallopian tube cancer primary peritoneal cancer confirmed	0.968	Ovary Cancer	C04.588.322.455|C13.351.500.056.630.705|C13.351.937.418.685|C19.344.410|C19.391.630.705	1.000
NCT04348032	inclusion	Patients were diagnosed with ovarian cancer, fallopian tube cancer or primary peritoneal cancer confirmed by previous pathology, and the pathological type was non-mucinous adenocarcinoma.There were previous surgical wax preservation	word_scores:cancer	ovarian cancer fallopian tube cancer primary peritoneal cancer confirmed	0.968	Fallopian Tube Cancer	C04.588.945.418.365|C13.351.500.056.390.390|C13.351.937.418.365	1.000
NCT04348032	inclusion	Initial platinum-resistant relapse, the recurrence time was less than 6 months after the last chemotherapy	word_scores:treatment	chemotherapy	0.974	Drug Therapy	E02.319	1.000
NCT04348032	inclusion	Complicated with malignant pleural effusion or ascites, or with recurrent lesions that can be evaluated clinically	word_scores:chronic_disease	ascites	0.880	Ascites	C23.550.081	1.000
NCT04348032	inclusion	Complicated with malignant pleural effusion or ascites, or with recurrent lesions that can be evaluated clinically	word_scores:cancer	malignant pleural effusion	0.704	Pleural Effusion, Malignant	C04.588.894.797.640.700|C08.528.652.700|C08.528.694.700|C08.785.640.700	1.000
NCT04348032	inclusion	ECOG physical status score 0 or 1	word_scores:clinical_variable	ecog physical status score	0.943
NCT04348032	inclusion	In the previous treatment, there was no antivascular targeted therapy	word_scores:treatment	treatment	0.779	Therapeutics	E02	1.000
NCT04348032	inclusion	In the previous treatment, there was no antivascular targeted therapy	word_scores:treatment	targeted therapy	0.861
NCT04348032	inclusion	Patients without pleural effusion or ascites should be confirmed by CT or MRI according to the standard of RECIST1.1 version, requiring the patient to have at least one measurable focus as the target focus. If the target focus is a lymph node with a short diameter of more than 1.5 cm, and the target focus is not suitable for surgical treatment, the target focus has not received radiotherapy or relapsed in the radiotherapy field	word_scores:chronic_disease	pleural effusion ascites should	0.866	Pleural Effusion	C08.528.652	1.000
NCT04348032	inclusion	Patients without pleural effusion or ascites should be confirmed by CT or MRI according to the standard of RECIST1.1 version, requiring the patient to have at least one measurable focus as the target focus. If the target focus is a lymph node with a short diameter of more than 1.5 cm, and the target focus is not suitable for surgical treatment, the target focus has not received radiotherapy or relapsed in the radiotherapy field	word_scores:treatment	ct magnetic resonance imaging according	0.738
NCT04348032	inclusion	Patients without pleural effusion or ascites should be confirmed by CT or MRI according to the standard of RECIST1.1 version, requiring the patient to have at least one measurable focus as the target focus. If the target focus is a lymph node with a short diameter of more than 1.5 cm, and the target focus is not suitable for surgical treatment, the target focus has not received radiotherapy or relapsed in the radiotherapy field	word_scores:treatment	surgical treatment	0.834
NCT04348032	inclusion	Patients without pleural effusion or ascites should be confirmed by CT or MRI according to the standard of RECIST1.1 version, requiring the patient to have at least one measurable focus as the target focus. If the target focus is a lymph node with a short diameter of more than 1.5 cm, and the target focus is not suitable for surgical treatment, the target focus has not received radiotherapy or relapsed in the radiotherapy field	word_scores:treatment	radiotherapy	0.727	Radiotherapy	E02.815	1.000
NCT04348032	inclusion	The baseline blood routine conforms to the following criteria: neutrophil count ≥ 1.5x109 /L	word_scores:clinical_variable	neutrophil count	1.000
NCT04348032	inclusion	The baseline blood routine conforms to the following criteria: platelet count ≥ 100x109 PG L	word_scores:clinical_variable	platelet count	0.996	Platelet Count	E01.370.225.500.195.107.740|E01.370.225.625.107.700|E01.370.225.625.625.625|E05.200.500.195.107.740|E05.200.625.107.700|E05.200.625.625.625|E05.242.195.107.740|G04.140.107.740|G09.188.105.700	1.000
NCT04348032	inclusion	The baseline blood routine conforms to the following criteria: hemoglobin ≥ 9g/dL (blood transfusion is allowed to achieve or maintain this target)	word_scores:clinical_variable	hemoglobin	0.995	Hemoglobin E|Hemoglobins	D12.776.124.400|D12.776.124.400.463.375|D12.776.422.316.762|D12.776.422.316.762.426.375	1.000
NCT04348032	inclusion	The baseline blood routine conforms to the following criteria: total bilirubin<1.5 normal limit (ULN)	word_scores:clinical_variable	bilirubin	0.988	Bilirubin	D03.383.129.578.840.249.184|D03.633.400.909.249.184|D04.345.783.249.184|D23.767.193.184	1.000
NCT04348032	inclusion	The baseline blood routine conforms to the following criteria: glutamic oxaloacetic transaminase (AST), glutamic pyruvic transaminase (ALT)<2.5xULN, which is allowed<5xULN in patients with liver metastasis	word_scores:clinical_variable	glutamic oxaloacetic transaminase glutamic pyruvic transaminase	0.992	Aspartate Aminotransferases	D08.811.913.477.700.225	1.000
NCT04348032	inclusion	The baseline blood routine conforms to the following criteria: glutamic oxaloacetic transaminase (AST), glutamic pyruvic transaminase (ALT)<2.5xULN, which is allowed<5xULN in patients with liver metastasis	word_scores:clinical_variable	glutamic oxaloacetic transaminase glutamic pyruvic transaminase	0.992	Alanine Transaminase	D08.811.913.477.700.100	1.000
NCT04348032	inclusion	The baseline blood routine conforms to the following criteria: glutamic oxaloacetic transaminase (AST), glutamic pyruvic transaminase (ALT)<2.5xULN, which is allowed<5xULN in patients with liver metastasis	word_scores:cancer	liver metastasis	0.948
NCT04348032	inclusion	The baseline blood routine conforms to the following criteria: Serum creatinine ≤ 1.25xULN or calculated creatinine clearance ≥ 50mL/min	word_scores:clinical_variable	serum creatinine	0.988
NCT04348032	inclusion	The baseline blood routine conforms to the following criteria: Serum creatinine ≤ 1.25xULN or calculated creatinine clearance ≥ 50mL/min	word_scores:clinical_variable	calculated creatinine clearance	0.889
NCT04348032	exclusion	Have received more than two chemotherapy regimens in the past	word_scores:treatment	regimens	0.992
NCT04348032	exclusion	other malignant tumors have occurred within 5 years (except adequately treated cervical carcinoma in situ or skin squamous cell carcinoma, or controlled basal cell carcinoma of the skin)	word_scores:cancer	malignant tumors have	0.977
NCT04348032	exclusion	other malignant tumors have occurred within 5 years (except adequately treated cervical carcinoma in situ or skin squamous cell carcinoma, or controlled basal cell carcinoma of the skin)	word_scores:cancer	cervical carcinoma situ skin squamous cell carcinoma	0.984	Cancer of the Uterine Cervix	C04.588.945.418.948.850|C13.351.500.852.593.131|C13.351.500.852.762.850|C13.351.937.418.875.850	1.000
NCT04348032	exclusion	other malignant tumors have occurred within 5 years (except adequately treated cervical carcinoma in situ or skin squamous cell carcinoma, or controlled basal cell carcinoma of the skin)	word_scores:cancer	basal cell carcinoma skin	0.942	Carcinoma, Basal Cell	C04.557.470.200.165|C04.557.470.565.165	0.773
NCT04348032	exclusion	Patients with hypertension that cannot be reduced to normal range after antihypertensive treatment (systolic blood pressure ≥ 140mmHg or diastolic blood pressure ≥ 90 mmHg)	word_scores:chronic_disease	hypertension	0.966	Hypertension	C14.907.489	1.000
NCT04348032	exclusion	Patients with hypertension that cannot be reduced to normal range after antihypertensive treatment (systolic blood pressure ≥ 140mmHg or diastolic blood pressure ≥ 90 mmHg)	word_scores:treatment	antihypertensive treatment	0.860	Antihypertensive Agents	D27.505.954.411.162	0.929
NCT04348032	exclusion	Patients with hypertension that cannot be reduced to normal range after antihypertensive treatment (systolic blood pressure ≥ 140mmHg or diastolic blood pressure ≥ 90 mmHg)	word_scores:clinical_variable	systolic blood pressure	0.914
NCT04348032	exclusion	Patients with hypertension that cannot be reduced to normal range after antihypertensive treatment (systolic blood pressure ≥ 140mmHg or diastolic blood pressure ≥ 90 mmHg)	word_scores:clinical_variable	diastolic blood pressure	0.938
NCT04348032	exclusion	Suffer from myocardial ischemia or myocardial infarction above II grade and poorly controlled arrhythmias (including QTc interval ≥ 470ms in females)	word_scores:clinical_variable	qtc interval	0.719
NCT04348032	exclusion	Suffer from myocardial ischemia or myocardial infarction above II grade and poorly controlled arrhythmias (including QTc interval ≥ 470ms in females)	word_scores:gender	females	0.961	Women	M01.975	1.000
NCT04348032	exclusion	Suffer from myocardial ischemia or myocardial infarction above II grade and poorly controlled arrhythmias (including QTc interval ≥ 470ms in females)	word_scores:chronic_disease	myocardial ischemia myocardial infarction above	0.908	Myocardial Ischemia	C14.280.647|C14.907.585	1.000
NCT04348032	exclusion	Suffer from myocardial ischemia or myocardial infarction above II grade and poorly controlled arrhythmias (including QTc interval ≥ 470ms in females)	word_scores:chronic_disease	myocardial ischemia myocardial infarction above	0.908	Myocardial Infarction	C14.280.647.500|C14.907.585.500|C23.550.513.355.750|C23.550.717.489.750	0.750
NCT04348032	exclusion	According to the NYHA standard, there were previous or present cardiac insufficiency of grade II or above, or color Doppler echocardiography showed that the left ventricular ejection fraction ((LVEF)) was less than 50% or the lower limit of the normal value	word_scores:chronic_disease	cardiac insufficiency	0.773
NCT04348032	exclusion	According to the NYHA standard, there were previous or present cardiac insufficiency of grade II or above, or color Doppler echocardiography showed that the left ventricular ejection fraction ((LVEF)) was less than 50% or the lower limit of the normal value	word_scores:clinical_variable	left ventricular ejection fraction was	0.922
NCT04348032	exclusion	Abnormal coagulation function (INR>1.5 or prothrombin time (PT) > ULN+4 seconds or APTT>1.5xULN), with bleeding tendency or undergoing thrombolytic or anticoagulant therapy	word_scores:treatment	thrombolytic anticoagulant therapy	0.935	Thrombolytic Therapy	E02.319.913	1.000
NCT04348032	exclusion	Abnormal coagulation function (INR>1.5 or prothrombin time (PT) > ULN+4 seconds or APTT>1.5xULN), with bleeding tendency or undergoing thrombolytic or anticoagulant therapy	word_scores:treatment	thrombolytic anticoagulant therapy	0.935	Anticoagulants	D27.505.954.502.119	1.000
NCT04348032	exclusion	Abnormal coagulation function (INR>1.5 or prothrombin time (PT) > ULN+4 seconds or APTT>1.5xULN), with bleeding tendency or undergoing thrombolytic or anticoagulant therapy	word_scores:clinical_variable	inr	0.823	International Normalized Ratio	E01.370.225.625.115.320|E05.200.625.115.320	1.000
NCT04348032	exclusion	Abnormal coagulation function (INR>1.5 or prothrombin time (PT) > ULN+4 seconds or APTT>1.5xULN), with bleeding tendency or undergoing thrombolytic or anticoagulant therapy	word_scores:clinical_variable	prothrombin time	0.906	Prothrombin Time	E01.370.225.625.115.610|E05.200.625.115.610|G09.188.680	1.000
NCT04348032	exclusion	Abnormal coagulation function (INR>1.5 or prothrombin time (PT) > ULN+4 seconds or APTT>1.5xULN), with bleeding tendency or undergoing thrombolytic or anticoagulant therapy	word_scores:clinical_variable	aptt	0.776
NCT04348032	exclusion	There were significant clinical bleeding symptoms or definite bleeding tendency in the first 3 months, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, baseline fecal occult blood or above, or suffering from vasculitis	word_scores:chronic_disease	gastrointestinal bleeding hemorrhagic gastric ulcer	0.937	Gastrointestinal Tract	A03.556	1.000
NCT04348032	exclusion	Major surgical operations or severe traumatic injuries, fractures or ulcers occurred within the first 4 weeks of randomization	word_scores:chronic_disease	traumatic injuries	0.771
NCT04348032	exclusion	Major surgical operations or severe traumatic injuries, fractures or ulcers occurred within the first 4 weeks of randomization	word_scores:chronic_disease	ulcers occurred	0.835
NCT04348032	exclusion	Major surgical operations or severe traumatic injuries, fractures or ulcers occurred within the first 4 weeks of randomization	word_scores:treatment	major surgical operations	0.850
NCT04348032	exclusion	There are significant factors affecting oral drug absorption, such as inability to swallow, chronic diarrhea and intestinal obstruction	word_scores:treatment	oral drug absorption	0.725
NCT04348032	exclusion	There are significant factors affecting oral drug absorption, such as inability to swallow, chronic diarrhea and intestinal obstruction	word_scores:chronic_disease	chronic diarrhea intestinal obstruction	0.887	Intestinal Obstruction	C06.405.469.531	1.000
NCT04348032	exclusion	Urine routine indicates urinary protein ≥++, or confirms 24-hour urinary protein ≥ 1.0g	word_scores:clinical_variable	urine routine indicates urinary protein	0.897
NCT04348032	exclusion	Urine routine indicates urinary protein ≥++, or confirms 24-hour urinary protein ≥ 1.0g	word_scores:clinical_variable	confirms 24-hour urinary protein	0.787
NCT04348032	exclusion	Allergic or heterogeneous reactions to doxorubicin and / or related substances	word_scores:allergy_name	doxorubicin	0.993	Doxorubicin	D02.455.426.559.847.562.050.200.175|D04.615.562.050.200.175|D09.408.051.059.200.175	1.000
NCT04348032	exclusion	The cumulative dose of doxorubicin (including previous anthracycline, if any) is expected to reach or exceed 550 mg after 4 courses of doxorubicin liposome injection treatment	word_scores:treatment	doxorubicin	0.934	Doxorubicin	D02.455.426.559.847.562.050.200.175|D04.615.562.050.200.175|D09.408.051.059.200.175	1.000
NCT04348032	exclusion	The cumulative dose of doxorubicin (including previous anthracycline, if any) is expected to reach or exceed 550 mg after 4 courses of doxorubicin liposome injection treatment	word_scores:treatment	anthracycline	0.909	Anthracyclines	D02.455.426.559.847.562.050|D04.615.562.050|D09.408.051.059	0.909
NCT04348032	exclusion	The cumulative dose of doxorubicin (including previous anthracycline, if any) is expected to reach or exceed 550 mg after 4 courses of doxorubicin liposome injection treatment	word_scores:treatment	doxorubicin liposome injection treatment	0.872
NCT04348032	exclusion	Uncontrollable arrhythmias or electrocardiograms abnormalities determined by the lead researcher to be at risk	word_scores:chronic_disease	arrhythmias electrocardiograms abnormalities determined	0.971	Arrhythmias, Cardiac	C14.280.067|C23.550.073	0.875
NCT04348032	exclusion	A history of doxorubicin liposome therapy in recent half a year	word_scores:treatment	doxorubicin liposome therapy	0.989
NCT04348032	exclusion	Have previously received local radiotherapy of the pelvis or lower abdomen	word_scores:treatment	radiotherapy	0.996	Radiotherapy	E02.815	1.000
NCT04348006	inclusion	Newly diagnosis Multiple myeloma with CRAB (C: hypercalcemia, R: renal impairment, A: anemia, and B: bone lesions)	word_scores:cancer	multiple myeloma	0.896	Multiple Myeloma	C04.557.595.500|C14.907.454.460|C15.378.147.780.650|C15.378.463.515.460|C20.683.515.845|C20.683.780.650	1.000
NCT04348006	inclusion	Newly diagnosis Multiple myeloma with CRAB (C: hypercalcemia, R: renal impairment, A: anemia, and B: bone lesions)	word_scores:chronic_disease	hypercalcemia	0.896	Hypercalcemia	C18.452.174.451|C18.452.950.340	1.000
NCT04348006	inclusion	Newly diagnosis Multiple myeloma with CRAB (C: hypercalcemia, R: renal impairment, A: anemia, and B: bone lesions)	word_scores:chronic_disease	renal impairment	0.880	Kidney	A05.810.453	1.000
NCT04348006	inclusion	Newly diagnosis Multiple myeloma with CRAB (C: hypercalcemia, R: renal impairment, A: anemia, and B: bone lesions)	word_scores:chronic_disease	anemia	0.946	Anemia	C15.378.071	1.000
NCT04348006	exclusion	Smoldering MM	word_scores:cancer	smoldering multiple myeloma	0.975	Smoldering Multiple Myeloma	C04.834.794|C15.378.147.542.820|C15.378.147.780.838|C20.683.460.820|C20.683.780.838	1.000
NCT04347252	inclusion	Healthy, fasting glucose values < 6 mM, A1c < 6%, and no first degree family members with T2DM	word_scores:clinical_variable	fasting glucose values	0.969
NCT04347252	inclusion	Healthy, fasting glucose values < 6 mM, A1c < 6%, and no first degree family members with T2DM	word_scores:clinical_variable	a1c	0.934
NCT04347252	exclusion	Active infectious, malignant or inflammatory conditions; unstable angina or uncompensated heart failure; pulmonary disorders including COPD and asthma; malabsorptive GI disease; significant hepatic disease; renal insufficiency (eGFR < 50 ml/min/kg); anemia (hematocrit < 34%); pregnancy; and uncontrolled hypertension. Subjects will be excluded if they require daily medications that alter glucose metabolism or GI function (glucocorticoids, psychotropics, narcotics, metoclopramide)	word_scores:chronic_disease	infectious malignant inflammatory conditions unstable angina uncompensated heart failure pulmonary disorders copd asthma malabsorptive gastrointestinal disease	0.904
NCT04347252	exclusion	Active infectious, malignant or inflammatory conditions; unstable angina or uncompensated heart failure; pulmonary disorders including COPD and asthma; malabsorptive GI disease; significant hepatic disease; renal insufficiency (eGFR < 50 ml/min/kg); anemia (hematocrit < 34%); pregnancy; and uncontrolled hypertension. Subjects will be excluded if they require daily medications that alter glucose metabolism or GI function (glucocorticoids, psychotropics, narcotics, metoclopramide)	word_scores:chronic_disease	hepatic disease renal insufficiency	0.950
NCT04347252	exclusion	Active infectious, malignant or inflammatory conditions; unstable angina or uncompensated heart failure; pulmonary disorders including COPD and asthma; malabsorptive GI disease; significant hepatic disease; renal insufficiency (eGFR < 50 ml/min/kg); anemia (hematocrit < 34%); pregnancy; and uncontrolled hypertension. Subjects will be excluded if they require daily medications that alter glucose metabolism or GI function (glucocorticoids, psychotropics, narcotics, metoclopramide)	word_scores:chronic_disease	anemia	0.922	Anemia	C15.378.071	1.000
NCT04347252	exclusion	Active infectious, malignant or inflammatory conditions; unstable angina or uncompensated heart failure; pulmonary disorders including COPD and asthma; malabsorptive GI disease; significant hepatic disease; renal insufficiency (eGFR < 50 ml/min/kg); anemia (hematocrit < 34%); pregnancy; and uncontrolled hypertension. Subjects will be excluded if they require daily medications that alter glucose metabolism or GI function (glucocorticoids, psychotropics, narcotics, metoclopramide)	word_scores:chronic_disease	hypertension	0.810	Hypertension	C14.907.489	1.000
NCT04347252	exclusion	Active infectious, malignant or inflammatory conditions; unstable angina or uncompensated heart failure; pulmonary disorders including COPD and asthma; malabsorptive GI disease; significant hepatic disease; renal insufficiency (eGFR < 50 ml/min/kg); anemia (hematocrit < 34%); pregnancy; and uncontrolled hypertension. Subjects will be excluded if they require daily medications that alter glucose metabolism or GI function (glucocorticoids, psychotropics, narcotics, metoclopramide)	word_scores:clinical_variable	egfr	0.965
NCT04347252	exclusion	Active infectious, malignant or inflammatory conditions; unstable angina or uncompensated heart failure; pulmonary disorders including COPD and asthma; malabsorptive GI disease; significant hepatic disease; renal insufficiency (eGFR < 50 ml/min/kg); anemia (hematocrit < 34%); pregnancy; and uncontrolled hypertension. Subjects will be excluded if they require daily medications that alter glucose metabolism or GI function (glucocorticoids, psychotropics, narcotics, metoclopramide)	word_scores:clinical_variable	hematocrit	0.824	Hematocrit	E01.370.225.625.400|E05.200.625.400|G09.188.370.374	1.000
NCT04347252	exclusion	Active infectious, malignant or inflammatory conditions; unstable angina or uncompensated heart failure; pulmonary disorders including COPD and asthma; malabsorptive GI disease; significant hepatic disease; renal insufficiency (eGFR < 50 ml/min/kg); anemia (hematocrit < 34%); pregnancy; and uncontrolled hypertension. Subjects will be excluded if they require daily medications that alter glucose metabolism or GI function (glucocorticoids, psychotropics, narcotics, metoclopramide)	word_scores:pregnancy	pregnancy	0.772	Pregnancy	G08.686.784.769	1.000
NCT04347252	exclusion	Active infectious, malignant or inflammatory conditions; unstable angina or uncompensated heart failure; pulmonary disorders including COPD and asthma; malabsorptive GI disease; significant hepatic disease; renal insufficiency (eGFR < 50 ml/min/kg); anemia (hematocrit < 34%); pregnancy; and uncontrolled hypertension. Subjects will be excluded if they require daily medications that alter glucose metabolism or GI function (glucocorticoids, psychotropics, narcotics, metoclopramide)	word_scores:treatment	glucocorticoids psychotropics narcotics metoclopramide	0.822	Glucocorticoids	D06.472.040.543|D27.505.696.399.472.488	1.000
NCT04347252	exclusion	Active infectious, malignant or inflammatory conditions; unstable angina or uncompensated heart failure; pulmonary disorders including COPD and asthma; malabsorptive GI disease; significant hepatic disease; renal insufficiency (eGFR < 50 ml/min/kg); anemia (hematocrit < 34%); pregnancy; and uncontrolled hypertension. Subjects will be excluded if they require daily medications that alter glucose metabolism or GI function (glucocorticoids, psychotropics, narcotics, metoclopramide)	word_scores:treatment	glucocorticoids psychotropics narcotics metoclopramide	0.822	Narcotics	D27.505.696.277.600|D27.505.696.663.850.014.760|D27.505.954.427.040.550|D27.505.954.427.210.600	1.000
NCT04347252	exclusion	Active infectious, malignant or inflammatory conditions; unstable angina or uncompensated heart failure; pulmonary disorders including COPD and asthma; malabsorptive GI disease; significant hepatic disease; renal insufficiency (eGFR < 50 ml/min/kg); anemia (hematocrit < 34%); pregnancy; and uncontrolled hypertension. Subjects will be excluded if they require daily medications that alter glucose metabolism or GI function (glucocorticoids, psychotropics, narcotics, metoclopramide)	word_scores:treatment	glucocorticoids psychotropics narcotics metoclopramide	0.822	Metoclopramide	D02.065.277.573|D02.241.223.100.050.500.647|D02.241.223.100.100.510|D02.241.223.100.200.750|D02.241.223.100.300.350.625|D02.241.511.390.350.625|D02.455.426.559.389.127.020.937.647|D02.455.426.559.389.127.085.510|D02.455.426.559.389.127.250.750|D02.455.426.559.389.127.281.350.625|D02.455.426.559.389.657.654.638.625	1.000
NCT04344847	exclusion	previous gastric surgery	word_scores:treatment	gastric surgery	0.998
NCT04344847	exclusion	patients with hiatus hernia	word_scores:chronic_disease	hiatus hernia	0.985	Hernia, Hiatal	C23.300.707.500.467	1.000
NCT04344678	inclusion	Patients were requested to be free of all the psychotropic and anti-inflammatory medications for at least 4 weeks before participating in the study	word_scores:treatment	psychotropic anti-inflammatory medications	0.899
NCT04344678	exclusion	Patients with bipolar I or bipolar II disorder	word_scores:chronic_disease	bipolar i bipolar ii disorder	0.973	Bipolar Disorder	F03.084.500	0.812
NCT04344678	exclusion	Patients with personality disorders	word_scores:chronic_disease	personality disorders	0.999	Personality Disorders	F03.675	1.000
NCT04344678	exclusion	Patients with eating disorders	word_scores:chronic_disease	eating disorders	0.999	Eating Disorders	F03.400	1.000
NCT04344678	exclusion	Patients with concurrent active medical condition	word_scores:chronic_disease	medical condition	0.934
NCT04344678	exclusion	Patients with history of seizures	word_scores:chronic_disease	seizures	1.000	Seizures	C10.597.742|C23.888.592.742	1.000
NCT04344678	exclusion	Patients with history of receiving Electroconvulsive therapy (ECT)	word_scores:treatment	electroconvulsive therapy	0.996	Electroconvulsive Therapy	F04.570.200.583|F04.669.224.300	1.000
NCT04344678	exclusion	Patients with inflammatory disorders	word_scores:chronic_disease	inflammatory disorders	1.000
NCT04344678	exclusion	Patients with allergy or contraindications to the used medications	word_scores:allergy_name	medications	0.821	Pharmaceutical Preparations	D26	0.875
NCT04344678	exclusion	Patients with finally pregnant or lactating females	word_scores:pregnancy	finally pregnant	0.907
NCT04344678	exclusion	Patients with finally pregnant or lactating females	word_scores:gender	females	0.999	Women	M01.975	1.000
NCT04344678	exclusion	Cardiovascular disorders	word_scores:chronic_disease	cardiovascular disorders	1.000
NCT04344678	exclusion	Severe renal impairment: creatinine clearance of ≤ 25 ml/min	word_scores:chronic_disease	severe renal impairment	0.875	Kidney	A05.810.453	1.000
NCT04344678	exclusion	Severe renal impairment: creatinine clearance of ≤ 25 ml/min	word_scores:clinical_variable	creatinine clearance	0.988
NCT04344678	exclusion	Moderate or severe hepatic impairment	word_scores:chronic_disease	hepatic impairment	0.991	Hepatica	B01.650.940.800.575.912.250.836.750	0.800
NCT04344470	inclusion	Able to give informed consent	word_scores:contraception_consent	give informed consent	0.725
NCT04344470	inclusion	Fluent in English	word_scores:language_fluency	fluent english	0.998	Language Fluency, English	LF01.01	0.769
NCT04344470	exclusion	Self-reported consumption of >14 alcoholic drinks/week for a man and >7 alcoholic drinks/week for a woman	word_scores:gender	man	0.906	Humans|Men	B01.050.150.900.649.313.988.400.112.400.400|M01.390	1.000
NCT04344470	exclusion	Self-reported consumption of >14 alcoholic drinks/week for a man and >7 alcoholic drinks/week for a woman	word_scores:gender	woman	0.991	Women	M01.975	1.000
NCT04344470	exclusion	Abnormal findings on neurological examination	word_scores:treatment	neurological examination	0.911	Neurologic Examination	E01.370.376.550|E01.370.600.550	1.000
NCT04344470	exclusion	History of current brain tumor, stroke, head trauma with loss of consciousness, epilepsy, or seizures	word_scores:cancer	brain tumor	0.944	Brain Neoplasms	C04.588.614.250.195|C10.228.140.211|C10.551.240.250	1.000
NCT04344470	exclusion	History of current brain tumor, stroke, head trauma with loss of consciousness, epilepsy, or seizures	word_scores:chronic_disease	stroke head trauma	0.903	Stroke	C10.228.140.300.775|C14.907.253.855	1.000
NCT04344470	exclusion	History of current brain tumor, stroke, head trauma with loss of consciousness, epilepsy, or seizures	word_scores:chronic_disease	stroke head trauma	0.903	Craniocerebral Trauma	C10.900.300|C26.915.300	1.000
NCT04344470	exclusion	History of current brain tumor, stroke, head trauma with loss of consciousness, epilepsy, or seizures	word_scores:chronic_disease	epilepsy	0.939	Epilepsy	C10.228.140.490	1.000
NCT04344470	exclusion	History of current brain tumor, stroke, head trauma with loss of consciousness, epilepsy, or seizures	word_scores:chronic_disease	seizures	0.983	Seizures	C10.597.742|C23.888.592.742	1.000
NCT04344470	exclusion	Current episode of major depression or any major psychiatric illness	word_scores:chronic_disease	major depression	0.891
NCT04344470	exclusion	Current episode of major depression or any major psychiatric illness	word_scores:chronic_disease	psychiatric illness	0.991	Mental Disorders	F03	1.000
NCT04343391	inclusion	Emotional Disorder	word_scores:chronic_disease	emotional disorder	0.999
NCT04343391	exclusion	Severe mental disorder	word_scores:chronic_disease	severe mental disorder	0.867	Mental Disorder		1.000
NCT04343391	exclusion	Severe depression	word_scores:chronic_disease	severe depression	0.845	Depression	F01.145.126.350	1.000
NCT04343014	inclusion	ASA graded I~II class	word_scores:clinical_variable	asa graded i~ii class	0.915
NCT04343014	inclusion	scheduled for elective surgery requiring orotracheal intubation	word_scores:treatment	elective surgery requiring orotracheal intubation	0.899
NCT04343014	exclusion	with organ transplant operations	word_scores:treatment	organ transplant operations	0.995
NCT04343014	exclusion	with thoracic and cardiac vascular surgery	word_scores:treatment	thoracic cardiac vascular surgery	0.984	Thoracica	B01.050.500.131.365.880	0.833
NCT04343014	exclusion	with severe cadiac or pulmonary disease	word_scores:chronic_disease	cadiac pulmonary disease	0.976	Lung Diseases	C08.381	1.000
NCT04342793	inclusion	Men or women ages 19 and over, under 75 years of age	word_scores:gender	men women ages	0.900	Men|Multiple Endocrine Neoplasia Type 2a|Multiple Endocrine Neoplasia Type 2b	C04.588.322.400.505|C04.588.322.400.510|C04.651.600.505|C04.651.600.510|C04.700.630.505|C04.700.630.510|C16.320.700.630.505|C16.320.700.630.510|C19.344.400.505|C19.344.400.510|M01.390	1.000
NCT04342793	inclusion	Patients diagnosed with NAFLD on abdominal ultrasonography and MRI	word_scores:chronic_disease	nafld	0.787	Non-alcoholic Fatty Liver Disease	C06.552.241.519	1.000
NCT04342793	inclusion	Patients diagnosed with NAFLD on abdominal ultrasonography and MRI	word_scores:treatment	abdominal ultrasonography magnetic resonance imaging	0.836	Magnetic Resonance Imaging	E01.370.350.825.500	1.000
NCT04342793	exclusion	Chronic liver disease (including hemochromatosis, liver cancer, autoimmune liver disease, viral hepatitis A, B, alcoholic liver disease	word_scores:chronic_disease	chronic liver disease	0.890
NCT04342793	exclusion	Chronic liver disease (including hemochromatosis, liver cancer, autoimmune liver disease, viral hepatitis A, B, alcoholic liver disease	word_scores:chronic_disease	hemochromatosis	0.958	Hemochromatosis	C16.320.565.618.337|C18.452.565.500.480|C18.452.648.618.337	1.000
NCT04342793	exclusion	Chronic liver disease (including hemochromatosis, liver cancer, autoimmune liver disease, viral hepatitis A, B, alcoholic liver disease	word_scores:chronic_disease	autoimmune liver disease viral hepatitis a b alcoholic liver disease	0.925	Hepatitis, Viral, Human	C01.925.440|C06.552.380.705	0.857
NCT04342793	exclusion	Chronic liver disease (including hemochromatosis, liver cancer, autoimmune liver disease, viral hepatitis A, B, alcoholic liver disease	word_scores:chronic_disease	autoimmune liver disease viral hepatitis a b alcoholic liver disease	0.925	Hepatitis B	C01.925.256.430.400|C01.925.440.435|C06.552.380.705.437	1.000
NCT04342793	exclusion	Chronic liver disease (including hemochromatosis, liver cancer, autoimmune liver disease, viral hepatitis A, B, alcoholic liver disease	word_scores:chronic_disease	autoimmune liver disease viral hepatitis a b alcoholic liver disease	0.925	Liver Diseases, Alcoholic	C06.552.645|C25.775.100.087.645	1.000
NCT04342793	exclusion	Chronic liver disease (including hemochromatosis, liver cancer, autoimmune liver disease, viral hepatitis A, B, alcoholic liver disease	word_scores:cancer	liver cancer	0.742	Cancer of Liver|Carcinoma, Hepatocellular	C04.557.470.200.025.255|C04.588.274.623|C04.588.274.623.160|C06.301.623|C06.301.623.160|C06.552.697|C06.552.697.160	1.000
NCT04342793	exclusion	Uncontrolled diabetes mellitus as defined by a HbA1c ≥ 9.0％ at Screening	word_scores:chronic_disease	diabetes mellitus	0.983	Diabetes Mellitus	C18.452.394.750|C19.246	1.000
NCT04342793	exclusion	Uncontrolled diabetes mellitus as defined by a HbA1c ≥ 9.0％ at Screening	word_scores:clinical_variable	hba1c	0.844
NCT04342793	exclusion	Patients who are allergic or hypersensitive to the drug or its constituents	word_scores:allergy_name	drug	0.817	Drug Therapy|Pharmaceutical Preparations	D26|E02.319	1.000
NCT04342793	exclusion	Pregnant or lactating women	word_scores:pregnancy	pregnant	0.999	Pregnancy	G08.686.784.769	1.000
NCT04342793	exclusion	Pregnant or lactating women	word_scores:gender	women	0.997	Women	M01.975	1.000
